Announcement
Announcement under Regulation 30 (LODR)-Updates on Acquisition 15 Sep - ZIM FZE completed approved investment in ZIM Scientific Office LLC, retaining 100% holding.
Source: Bse
Zim Laboratories Limited (ZIMLAB)
Small CapPharma stocks · Small cap · NSE
Zim Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 02:31 pm ISTDetails
Quote21 Oct, 02:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result06 Aug, 09:25 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +8.3% / mo · MACD − · sector +4.5pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -1.7% vs Nifty 500 -6.2%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ZIMLABD candles · FIT view+48.6%TODAY · PROVISIONALLatest price ₹127.85 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
-7.5%
RSI
41
MACD hist
-1.73
52W pos
68%
2026-10-21O ₹138.20H ₹143.00L ₹125.63C ₹127.85Vol 1.5L shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ZIMLABNifty PharmaNifty 500
- ZIMLAB
- +14.2%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +19.8 pp
Chart stats
19 Oct 2026- From 52W high
- -13.5%
- 52W range position
- 78%
- ATR (14)
- 6.3%
- Volume vs 20D
- 0.33x
- Avg traded value
- ₹2.7 Cr
- 20D price channel
- ₹130.5 - ₹159.8
₹159.8
₹59.3 - ₹159.8
₹8.8
Latest completed session
20-session average
49.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED17
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad22
Revenue +31.2% · PAT NDF YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model-6084.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence57
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 22/100margin compression · Rev +31% YoY
Filed 06 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹94.2 Cr | +31.2% | -10.5% |
| EBITDA | ₹2.5 Cr | -42.4% | -65.9% |
| Operating margin | 2.6% | -332 bps | -423 bps |
| PAT | ₹-4 Cr | NDF | -207.5% |
| PAT margin | -4.3% | -166 bps | -782 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 200.00
- P/B
- 2.47
- EV/EBITDA
- 18.04
- Market Cap
- 739.00Cr
Profitability
- ROE
- 1.59%
- ROCE
- 4.76%
- ROA
- 0.74%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 4.00%
- EPS 5Y
- -17.00%
- Revenue 3Y
- -2.00%
- EPS 3Y
- -44.00%
Balance Sheet
- Debt/Equity
- 0.43
- Interest Coverage
- 2.00×
- Altman Z
- 3.57
- Book Value
- 55.40
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 9/5
- OCF
- 50.00 Cr
- EPS TTM
- 0.76
Shareholding
- Promoter Hold
- 30.36%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 91%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 94.2-10.5% vs prev
Net Profit
₹ CrLatest: -4.0-207.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 41. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~7.2% over last month) — short-term momentum positive.
- RSI(14) at 41 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 20% off 52W high · 116% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
94
RS percentile
Stage 2 UptrendEstablished S2
1M return
+2.0%
3M return
+14.2%
6M return
+58.5%
1Y return
+100.4%
RS 1D
0
RS 20D
+1
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 25.5% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +9.6%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
05 May 2026
S2 age
118 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 199.3-3.57%
RS vs Nifty 500199
Valuation & peers
U-Score 17 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 17 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation2/30
Growth3/25
Quality0/20
Balance Sheet6/15
Cash Flow4/10
Piotroski
5/9 (+3)
Penalties
-1
Raw sum
17
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
17/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 6/15 to the score.
- Cash flow contributes 4/10 to the score.
- Growth contributes 3/25 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -6084.6%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
200.0
PB
2.5
EV/EBITDA
18.0
ROE
1.6%
ROCE
4.8%
FCF Yield
—
Debt/Equity
0.4
MoS
-6084.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
17
Previous: 17
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-6084.6%
Previous: -6583.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
17
17
17
17
17
17
17
17
17
17
17
17
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹30.78
-315.4% MoS
Growth-justified P/E
2.7
Growth-justified Value
₹2.07
-6084.6% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
VALIANTLAB
Small
Valiant Laboratories Limited
Healthcare Services
match 167
15
43.3
-1.2%
-4939%
OVERVALUED
KILITCH
Small
Kilitch Drugs (India) Limited
Healthcare Services
match 164
50
27.5
10.6%
+43%
FAIR VALUE
THEMISMED
Small
Themis Medicare Limited
Healthcare Services
match 164
18
—
0.4%
-2440%
OVERVALUED
LYKALABS
Small
Lyka Labs Limited
Healthcare Services
match 162
20
—
-10.2%
—
OVERVALUED
LOTUSEYE
Small
Lotus Eye Hospital and Institute Limited
Healthcare Services
match 161
13
1504.0
0.1%
-161992%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Zim Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
57Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 20th percentile of the scored universe and 14th percentile within Pharma. Main check: results consistency is weak at 27/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
68 docs text-extracted · 22 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
20th percentile
overall median 67 · Pharma: 14th pctile, median 70 · Small: 23rd pctile, median 66
Evidence depth
Financial-only
68 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
70
acceptable · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
27
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸9 years of positive FCF.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding fell 2.9%.
- ▸ROCE is low at 4.8%.
- ▸ROE is low at 1.6%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Zim Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Jul - The copy of newspaper publication regarding the Notice of Postal Ballot
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Jun - Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Jun - Newspaper Publication regarding the 42nd Annual General Meeting.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 5 Jun - Zim Laboratories filed its Annual Report for FY2025-26 and shared it on its website.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 May - Corrigendum to the Newspaper Publication dated 26.05.2026
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 20 May - The copies of newspaper publication regarding the financial results for the quarter and year ended 31.03.2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.